Company: PTHS
Filing Date: 2025-05-09
Form Type: PREM14C
Source: 0001140361-25-018219
Chunk: 775

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-05-09
Form: PREM14C
Chunk 775
---
 brought before the board of directors of the corporation for action or (iv) the contract or transaction is fair as to the corporation at the time it is authorized or approved;

WHEREAS , it is hereby disclosed or made known to the undersigned that Todd Davis, Ezra Friedberg, Dr. Richard Malamut and Chia-Lin Simmons, each a member of the Board, and Francis Knuettel II, the Company’s Chief Executive Officer and President, Chief Financial Officer, Treasurer, Secretary and member of the board of directors of the Company (the “ Board ”), will participate in the Financing and the other transactions contemplated by the Financing Documents and will have a financial interest in the Merger and the other transactions contemplated by the Merger Agreement;

WHEREAS , the undersigned are aware of all the material facts related to the Merger Agreement, the Merger, the Financing Documents, the Financing, and the other transactions contemplated by the Merger Agreement and the Financing Documents and have had an adequate opportunity to ask questions regarding, and investigate the nature of, the relationship and/or interests of Mr. Davis, Mr. Friedberg, Dr. Malamut, Ms. Simmons and Mr. Knuettel with and in connection with the Merger and the transactions contemplated by the Merger Agreement and the Financing and the transactions contemplated by the Financing Documents;

WHEREAS , if necessary to meet the listing requirements for listing the shares of Company Common Stock issuable upon conversion of the Series A Preferred Shares to be paid by the Company in the Merger pursuant to the Merger Agreement and issuable to the Investors pursuant to the Securities Purchase Agreement on NYSE American, the Board has determined that it is advisable and in the best interests of the Company to effectuate a reverse stock split of the common stock, par value $0.0001 per share, of the Company (the “ Company Common Stock ”), at a ratio of between 5:1 (five-to-one) and 100:1 (one hundred-to-one), as shall be determined by the Board immediately prior to the effectiveness of the Reverse Stock Split Amendment (as defined below), which shall include all registered, authorized, issued and outstanding shares of Company Common Stock (the “ Reverse Stock Split ”);

WHEREAS , in order to effectuate the Reverse Stock Split, the Company will amend its articles of incorporation accordingly (the “ Reverse Stock Split Certificate of Amendment ”);

WHEREAS , in connection with the Merger and pursuant to the Financing Documents, the Board has determined that it is advisable and in